The Burden of Familia Chylomicronemia Syndrome in Canadian Patients

Home / Intelligence / Scientific Publications / The Burden of Familia Chylomicronemia Syndrome in Canadian Patients

Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder characterized by persistent extreme hypertriglyceridemia as a result of lipoprotein lipase deficiency. Canada is an important region for FCS research due to the high prevalence rates. The burden of illness and quality of life of Canadian patients, however, have been inadequately addressed in the literature. The objective of this study is to understand the burden of illness of FCS on Canadian patients’ lives.

Authors

Daniel Gaudet, Michael Stevenson, Nelly Komari, Grace Trentin, Caroline Crowson, Nandini Hadker, Sophie Bernard

Journal

Lipids in Health and Disease

View publication

Related Intelligence

Scientific Publications

Treatment preferences among health care providers in the United States in selecting disease modifying therapies for multiple sclerosis: a discrete choice experiment study

Autoimmune screening panel (ASP) is routinely ordered as a part of diagnostic work-up in people with suspected multiple sclerosis (MS). However, data on prevalence and significance of ASP seropositivity in MS is scarce.

Scientific Publications

Burden of cremophor-related paclitaxel therapy on patients with ovarian cancer: A patient focused study from the United Kingdom, Germany, and Spain.

This study aimed to characterize the burden associated with CrEL-paclitaxel treatment on patients with ovarian cancer, including clinical, safety, and quality of life implications.

Scientific Publications

Evaluating the Clinical, Economic, and Societal Value of Rapid Diagnostic Testing in Emerging Markets: A Systematic Literature Review Assessing Infectious Diseases

This study aimed to synthesize published and other literature on the clinical, societal, and economic value of RDTs for infectious disease across Asia, Africa, and Latin America.